cho

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Choriogonadotropin beta (FE 999302), a recombinant human chorionic gonadotropin (rhCG), is a glycoprotein expressed by the PER.C6 human cell line. It is utilized in infertility research [1] [2].

Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody expressed in CHO cells, effectively competes with the virus Spike protein for binding to the CD26 receptor, thereby inhibiting viral invasion into host cells.

Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human IgG1 monoclonal antibody derived from CHO cells that effectively inhibits the interaction between the MERS-CoV spike protein and the DPP4 receptor[1].

Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody derived from CHO cells, designed to selectively bind the Spike (S1) protein, thereby preventing SARS virus infection in susceptible cells[1].

Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody produced from CHO cells, which specifically targets the S1 domain of the Spike protein in both SARS-CoV and SARS-CoV-2.

Anti-Spike-RBD mAb is a CHO cell-derived human monoclonal IgG1 antibody that potentially treats SARS-CoV-2 by blocking the interaction between the spike protein and ACE2[1].

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Zimberelimab (GLS-010) is a humanized monoclonal antibody targeting PD-1, with antitumor activity. It blocks the interaction between PD-L1, PD-L2, and PD-1 on the cell surface, and is used in studies of cervical cancer and non-small cell lung cancer.

Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.

Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).

Vandortuzumab is a humanised monoclonal antibody targeting STEAP1, commonly used as the targeting component of the synthetic ADC (antibody-drug conjugate) vandortuzumab vedotin, and is applicable for prostate cancer research.

Sirtratumab Vedotin (ASG-15ME) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets SLITRK6 covalently linked to the potent cytotoxic agent monomethyl auristatin E (MMAE). Sirtratumab Vedotin is designed to selectively deliver the microtubule-disrupting payload MMAE to tumor cells expressing the SLITRK6 antigen, granting it significant potential for research in bladder cancer and metastatic urothelial carcinoma.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal immunoglobulin G1 (IgG1) antibody specifically targeting the serum amyloid P component (SAP), a protein universally found in all types of amyloid deposits, and it possesses potential anti-amyloid activity by triggering an immunotherapeutic mechanism for the clearance of amyloid fibrils through macrophage-mediated phagocytosis, which can be applied in the research of amyloid light-chain (AL) amyloidosis and other systemic amyloid diseases.

Ecromeximab (KW2871) is a mouse chimeric monoclonal antibody targeting ganglioside GD3 and can be used to study malignant melanoma.

PF-03732010 is a CHO-expressed humanized antibody targeting P-calmodulin with anti-tumor and anti-metastatic activity, inhibiting primary tumor growth and metastatic progression.

Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody that specifically neutralizes transforming growth factor-beta (TGF-β, isoforms TGFB1/TGFB2) and is expressed in CHO-K1 cells. this agent is currently being studied preclinically and clinically for its significant ability to modulate the immunosuppressive tumor microenvironment in various oncological indications.

Coprelotamab (GB-221) is an IgG-κ monoclonal antibody that targets EGFR2, commonly produced in CHO DG44 (Chinese Hamster Ovary) cells [1].

Davoceticept (ALPN-202; CD80 vIgD-Fc), a monoclonal antibody that targets CTLA-4, consists of the (1-107) fragment of CD80 fused to the IGHG1 Fc domain via a peptidyl linker and is typically produced in CHO (Chinese Hamster Ovary) cells [1].